JHS Svendgaard Laboratories Analysis

dividend

Pros

Cons

• Unable to calculate sustainability of dividends as JHS Svendgaard Laboratories has not reported any payouts.
• Unable to evaluate JHS Svendgaard Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate JHS Svendgaard Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• JHS Svendgaard Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Debt is covered by short term assets, assets are 17.5x debt.
• JHS Svendgaard Laboratories's cash and other short term assets cover its long term commitments.
• The level of debt compared to net worth has been reduced over the past 5 years (124.4% vs 3.2% today).
• JHS Svendgaard Laboratories's level of debt (3.2%) compared to net worth is satisfactory (less than 40%).

Cons

• Operating cash flow is negative therefore debt is not well covered.
• High level of physical assets or inventory.

management

Pros

• The tenure for the JHS Svendgaard Laboratories board of directors is about average.
• Paramvir's remuneration is lower than average for companies of similar size in India.
• The average tenure for the JHS Svendgaard Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.

Cons

• Paramvir's compensation has increased whilst company is loss making.

misc

Pros

Cons

• JHS Svendgaard Laboratories is not covered by any analysts.
• JHS Svendgaard Laboratories has significant price volatility in the past 3 months.

past

Pros

Cons

• Unable to compare JHS Svendgaard Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
• JHS Svendgaard Laboratories does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
• JHS Svendgaard Laboratories used its assets less efficiently than the IN Personal Products industry average last year based on Return on Assets.
• It is difficult to establish if JHS Svendgaard Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
• It is difficult to establish if JHS Svendgaard Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
• Unable to compare JHS Svendgaard Laboratories's 1-year growth to the IN Personal Products industry average as it is not currently profitable.

value

Pros

• JHS Svendgaard Laboratories is good value based on assets compared to the IN Personal Products industry average.
• BSE:532771 is up 38.6% outperforming the Personal Products industry which returned 3.7% over the past month.
• BSE:532771 is up 38.6% outperforming the market in India which returned 8% over the past month.

Cons

• JHS Svendgaard Laboratories is loss making, we can't compare its value to the IN Personal Products industry average.
• JHS Svendgaard Laboratories is loss making, we can't compare the value of its earnings to the India market.
• 532771 underperformed the Personal Products industry which returned -5.3% over the past year.
• 532771 underperformed the Market in India which returned -14.5% over the past year.